SynOV1.1

Primary objective: To evaluate the safety and tolerability of SynOV1.1 adenovirus injection (abbreviated as SynOV1.1) in patients with locally advanced or metastatic solid tumors. Secondary objectives: 1. To investigate the biological distribution and biological effects of different doses of SynOV1.1 in patients with locally advanced or metastatic solid tumors. 2. To evaluate the immunogenicity of different doses of SynOV1.1 in patients with locally advanced or metastatic solid tumors. 3. To preliminarily evaluate the efficacy of different doses of SynOV1.1 in patients with locally advanced or metastatic solid tumors. Exploratory objectives: 1. To explore the anti-tumor immune response after administration of SynOV1.1 to treat patients with locally advanced or metastatic solid tumors and its correlation with safety, tolerability and efficacy. 2. To explore the level of baseline plasma exosomes to predict the anti-tumor efficacy of SynOV1.1 in patients with locally advanced or metastatic solid tumors.